Preoperative chemotherapy for bladder cancer

A standard waits to be optimally deployed


  • Guru Sonpavde MD,

    Corresponding author
    1. Texas Oncology-Deke Slayton Cancer Center, Webster, Texas
    2. Veterans Affairs Medical Center, Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas
    • 501 Medical Center Boulevard, Webster, TX 77598

    Search for more papers by this author
    • Fax: (281) 332-8429

  • Shahrokh F. Shariat MD, PhD

    1. Department of Urology and Medical Oncology, Weill Cornell Medical College, New York, New York
    Search for more papers by this author


This article is corrected by:

  1. Errata: Erratum Volume 119, Issue 3, 700, Article first published online: 14 August 2012

  • See referenced original article on pages 72-81, this issue.


A retrospective study of neoadjuvant gemcitabine plus cisplatin in the current issue of Cancer highlights the activity of this regimen and its low frequency of employment. Directions for the further development of neoadjuvant therapy for bladder cancer are discussed.